Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Oral Pain Medications Overtake Injectable Therapies as Preferred Treatment for Multiple Sclerosis Finds Frost & Sullivan - Long term clinical trials will increase likelihood of prescriptions receiving approval and adoption by physicians, finds Frost & Sullivan - LifeSciences.Frost.com
Oral Pain Medications Overtake Injectable Therapies as Preferred Treatment for Multiple Sclerosis Finds Frost & Sullivan

 

PRZOOM - /newswire/ - Mountain View, CA, United States, 2015/05/07 - Long term clinical trials will increase likelihood of prescriptions receiving approval and adoption by physicians, finds Frost & Sullivan - LifeSciences.Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The innovation of therapeutic platforms have driven the multiple sclerosis (MS) therapeutics market to enter a new phase of growth in the U.S. Oral therapies are revolutionizing the treatment paradigm of MS, offering enhanced dosing and patient compliance.

Analysis from Frost & Sullivan, A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market, finds that recent therapeutic advancements aim at improving the tolerability of existing products, specifically for interferon beta and glatiramer acetate. Developing anti-inflammatory medications has also been a key area of focus.

“Physicians prefer Avonex, Betaferon, Copaxone, Rebif or ABCRs as first line therapy because of the 10 years of clinical data establishing their efficacy and safety,” said Frost & Sullivan Healthcare Industry Analyst Aish Vivekanandan. “As is evident, clinical data substantiating the benefits of drugs will prove to be the driving factor in enabling rapid approvals from regulatory agencies.”

Relapsing-remitting multiple sclerosis (RRMS) is the most common form of MS particularly in the U.S. and Europe, and garners immense attention from drug manufacturers. Although, therapeutic drug development in the primary progressive multiple sclerosis (PPMS) segment leaves a lot to be desired.

Drug manufacturers are now investing in R&D to achieve a greater understanding of PPMS disease pathology and reach this untapped market. Clinical studies researching the treatment of progressive MS and investigating the effects of vitamin D in relapsing MS are also underway.

“Many pharmaceutical companies are gradually realizing the importance of long-term clinical studies for drugs,” noted Vivekanandan. “This awareness could spur pharmaceuticals to develop low-risk drugs for the treatment of MS and build a patient base in a market with huge unmet medical needs.”

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market is a Market Insight that is part of the Life Sciences (lifesciences.frost.com) Growth Partnership Service program. The analysis looks at MS pharmaceutical drugs currently in the market, as well as, drugs in the third phase of trials and poses a potential threat to competitors. The study offers a competitive evaluation of these drugs and the predicted outcome and impact of each of them.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.

The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on “the next big thing" | Register: Gain access to visionary innovation

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market / NEC3-52

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Oral Pain Medications Overtake Injectable Therapies as Preferred Treatment for Multiple Sclerosis Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan | Multiple Sclerosis
Contact: Kayla Belcher - Frost.com 
210-247-3870 kayla.belcher[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today